The direct medical costs of breast cancer in Iran: Analyzing the patient's level data from a cancer specific hospital in Isfahan

International Journal of Preventive Medicine

Volumn 4, Issue 7, 2013, Pages 748-754

  Davari, Majid ^a   Yazdanpanah, Farkhondeh ^b   Aslani, Abolfazl ^b   Hosseini, Mohsen ^c   Nazari, Ali Reza ^d   Mokarian, Fairborz ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Costs analysis; Direct medical cost; Iran

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER CENTER; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; HEALTH CARE COST; HEALTH SERVICE; HUMAN; IRAN; MAJOR CLINICAL STUDY;

EID: 84883874056     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001;2:133-40.
2. WHO. The World Health Report 2004; Changing History. Geneva: World Health Organisation; 2004.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
4. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-4.
5. Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: Pathways to personalized medicine. Clin Cancer Res 2008;14:7988-99.
6. Parkin D, Whelan S, Ferlay J. Cancer incidence in five continents. IARC (International Agency for Research Cancer) publication; 2002.
7. Hadi N, Sadeghi-Hassanabadi A, Talei AR, Arasteh MM, Kazerooni T. Assessment of a breast cancer screening programme in Shiraz, Islamic Republic of Iran. East Mediterr Health J 2002;8:386-92.
8. Harirchi I, Karbakhsh M, Kashefi A, Momtahen AJ. Breast cancer in Iran: Results of a multi-center study. Asian Pac J Cancer Prev 2004;5:24-7.
9. Hertz RP, McDonald MV, Kulig K. The burden of cancer in American adults. US: Outcomes Research Pfizer Global Pharmaceuticals; 2005.
10. Vydelingum NA, Wingrove BK, Emmanuel A, Taylor PH. Benefits and costs of policies to reduce cancer health disparities. In: Emmanuel A, Taylor PH editors. Economic Costs of Cancer Health Disparities. US: The Center to Reduce Cancer Health Disparities; 2004. p. 32-5.
11. Finkelstein E, Corso P. Cost-of-illness analyses for policy making: A cautionary tale of use and misuse. Expert Rev Pharmacoecon Outcomes Res 2003;3:367-9.
12. Ekwueme DU, Gardner JG, Subramanian S, Tangka FK, Bapat B, Richardson LC. Cost analysis of the National Breast and Cervical Cancer Early Detection Program: Selected states, 2003 to 2004. Cancer 2008;112:626-35.
13. Wittekind C, Compton CC, Greene FL, Sobin LH. TNM residual tumor classification revisited. Cancer 2002;94:2511-6.
14. Walley T, Strobl J. Cost of illness studies. In: Walley T, Haycox A, Boland A, editors. Pharmacoeconomics. London, UK: Churchill Livingston; 2004. p. 94.
15. Drummond MF, Sculpher MJ, Torrance GW, O' Brien BJ, Storddart GL. Cost analysis. In: MF Drummond, editor. Methods for Economic Evaluation of Health Care Programmes. 3rd ed. Oxford: Oxford University Press; 2005. p. 55.
16. Boutayeb S, Boutayeb A, Ahbeddou N, Boutayeb W, Ismail E, Tazi M, et al. Estimation of the cost of treatment by chemotherapy for early breast cancer in Morocco. Cost Eff Resour Alloc 2010;8:16.
17. Montazeri A, Vahdaninia M, Harirchi I, Harirchi AM, Sajadian A, Khaleghi F, et al. Breast cancer in Iran: Need for greater women awareness of warning signs and effective screening methods. Asia Pac Fam Med 2008;7:6.
18. Ebrahimi M, Vahdaninia M, Montazeri A. Risk factors for breast cancer in Iran: A case-control study. Breast Cancer Res 2002;4:R10.
19. Faradmal J, Kazemnejad A, Khodabakhshi R, Gohari MR, Hajizadeh E. Comparison of three adjuvant chemotherapy regimes using an extended log-logistic model in women with operable breast cancer. Asian Pac J Cancer Prev 2010;11:353-8.
20. Sadjadi A, Hislop TG, Bajdik C, Bashash M, Ghorbani A, Nouraie M, et al. Comparison of breast cancer survival in two populations: Ardabil, Iran and British Columbia, Canada. BMC Cancer 2009;9:381.
21. Harirchi I, Ebrahimi M, Zamani N, Jarvandi S, Montazeri A. Breast cancer in Iran: A review of 903 case records. Public Health 2000;114:143-5.
22. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, et al. Breast cancer in Iran: An epidemiological review. Breast J 2007;13:383-91.
23. Demographic Indicators [database on the Internet]. Iranian Statistical Centre, 2011. Available from: http://www.amar.org.ir/. [Cited on 2011 Jul 25].
24. Broekx S, Den Hond E, Torfs R, Remacle A, Mertens R, D'Hooghe T, et al. The costs of breast cancer prior to and following diagnosis. Eur J Health Econ 2011;12:311-7.
25. Razavi SE, Aaghajani H, Haghazali M, Nadali F, Ramazani R, Dabiri E, et al. The most common cancers in Iranian women. Iran J Public Health 2009;38:109-12.
26. Formenti SC, Arslan AA, Love SM. Global breast cancer: The lessons to bring home. Int J Breast Cancer 2012;1-7.
27. Verrill M. Chemotherapy for early-stage breast cancer: A brief history. Br J Cancer 2009;101(Suppl 1):S2-5.
28. Quaglia A, Lillini R, Casella C, Giachero G, Izzotti A, Vercelli M, et al. The combined effect of age and socio-economic status on breast cancer survival. Crit Rev Oncol Hematol 2011;77:210-20.
29. Teich N, Pepe C, Vieira FM, Teich V, Cintra M, Leibel F, et al. Retrospective cost analysis of breast cancer patients treated in a Brazilian outpatient cancer center. J Clin Oncol 28, 2010 (suppl; abstr e11026).
30. Barron JJ, Quimbo R, Nikam PT, Amonkar MM. Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat 2008;109:367-77.
31. Dahlberg L, Lundkvist J, Lindman H. Health care costs for treatment of disseminated breast cancer. Eur J Cancer 2009;45:1987-91.
32. Haddix A, Corso P, Gorsky D, Teutsch S. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. New York: Oxford University Press; 2003. p. 53-76.
33. Eheman CR, Benard VB, Blackman D, Lawson HW, Anderson C, Helsel W, et al. Breast cancer screening among low-income or uninsured women: Results from the National Breast and Cervical Cancer Early Detection Program, July 1995 to March 2002 (United States). Cancer Causes Control 2006;17:29-38.
34. Gold M. Panel on cost-effectiveness in health and medicine. Med Care 1996;34:DS197-9.
35. Davari M, Haycox A, Walley T. Health care financing in Iran; is privatization a good solution? Iran J Public Health 2012;41:14-23.